JMP Securities Upgrades Halozyme Therapeutics (HALO) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.42 +0.53%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
JMP Securities upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Market Outperform with a new price target of $9.00.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
For more ratings news on Halozyme Therapeutics click here and for the rating history of Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme Therapeutics (HALO) PT Raised to $78 at JPMorgan
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE®
Create E-mail Alert Related Categories
UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
